EZH2 and cancer: Either overexpression of EZH2 or inactivation of negative regulators of PRC2 augments the dependency of cancer cells on H3K27me3 and PRC2, indicating that PRC2 inhibition can augment the therapeutic vulnerability of cancer cells (74).